ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SYS6045

A development code.

Its studies are led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Jul 23, 20251 company-led study, 1 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group11 open or runningphase 2since Jul 23, 2025Jul 23, 2025Jul 30, 2027phase 2 · NCT07122063

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2025First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07122063 · 266 enrolled · China

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT07122063

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07122063Advanced Solid Tumors · China2Active, not recruitingJul 30, 2027266

How it is read

Names in the registry

  • “SYS6045”, 1 entry

Codes read as this program: SYS6045.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
    SYS6045 (CSPC Pharmaceutical Group): development program | ClinicalTrials.gg